Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2017

28.07.2017 | Clinical Study

Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis

verfasst von: Anne Fogli, Marie-Véronique Demattei, Laetitia Corset, Catherine Vaurs-Barrière, Emmanuel Chautard, Julian Biau, Jean-Louis Kémény, Catherine Godfraind, Bruno Pereira, Toufik Khalil, Nathalie Grandin, Philippe Arnaud, Michel Charbonneau, Pierre Verrelle

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Human malignant gliomas exhibit acquisition of either one of two telomere maintenance mechanisms, resulting from either reactivation of telomerase expression or activation of an alternative lengthening of telomeres (ALT) mechanism. In the present study, we analyzed 63 human malignant gliomas for the presence of ALT-specific extrachromosomal circles of telomeric DNA (C-circles) and measured telomerase expression, telomeric DNA content (Telo/Alu method), and telomeric repeat-containing RNAs (TERRA) levels. We also assessed histomolecular markers routinely used in clinical practice. The presence of C-circles significantly correlated with IDH1/2 mutation, MGMT exon 1 methylation, low Ki-67 immunostaining, increased telomeric DNA content, absence of functional ATRX protein and level of HTERT gene expression. In multivariate analysis, we observed a trend to a correlation between elevated TERRA levels and increased survival. Interestingly, the C-circles assay allowed to detect ALT activation in glioblastomas exhibiting wild-type IDH1/2 and ATRX expression. These results suggest that, after the correlations uncovered here have been confirmed on larger numbers of tumors, telomeric markers might be useful in improving diagnosis. They also point out to the utility of using the specific, sensitive and quantitative C-circle and Telo/Alu assays that can work with as few as 30 ng of tumor DNA.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Bryan TM, Englezou A, Dalla-Pozza L et al (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271–1274CrossRefPubMed Bryan TM, Englezou A, Dalla-Pozza L et al (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271–1274CrossRefPubMed
3.
Zurück zum Zitat Pickett HA, Reddel RR (2015) Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. Nat Struct Mol Biol 22:875–880CrossRefPubMed Pickett HA, Reddel RR (2015) Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. Nat Struct Mol Biol 22:875–880CrossRefPubMed
5.
Zurück zum Zitat Henson JD, Hannay JA, SmcCarthy SW et al (2005) A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 11:217–225PubMed Henson JD, Hannay JA, SmcCarthy SW et al (2005) A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 11:217–225PubMed
6.
Zurück zum Zitat Hakin-Smith V, Jellinek DA, Levy D et al (2003) Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. The Lancet 361:836–838CrossRef Hakin-Smith V, Jellinek DA, Levy D et al (2003) Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. The Lancet 361:836–838CrossRef
7.
Zurück zum Zitat McDonald KL, McDonnell J, Muntoni A et al (2010) Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 69:729–736CrossRefPubMed McDonald KL, McDonnell J, Muntoni A et al (2010) Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 69:729–736CrossRefPubMed
8.
Zurück zum Zitat Heaphy CM, de Wilde RF, Jiao Y et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 1333:425CrossRef Heaphy CM, de Wilde RF, Jiao Y et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 1333:425CrossRef
9.
Zurück zum Zitat Bérubé NG (2011) ATRX in chromatin assembly and genomearchitecture during development and disease. Biochem Cell Biol 89:435–444CrossRefPubMed Bérubé NG (2011) ATRX in chromatin assembly and genomearchitecture during development and disease. Biochem Cell Biol 89:435–444CrossRefPubMed
10.
Zurück zum Zitat Henson JD, Cao Y, Huschtscha LI et al (2009) DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol 27:1181–1186CrossRefPubMed Henson JD, Cao Y, Huschtscha LI et al (2009) DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol 27:1181–1186CrossRefPubMed
11.
12.
Zurück zum Zitat Fogli A, Chautard E, Vaurs-Barrière C et al (2016) The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients’ survival. Carcinogenesis 37:169–176CrossRefPubMed Fogli A, Chautard E, Vaurs-Barrière C et al (2016) The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients’ survival. Carcinogenesis 37:169–176CrossRefPubMed
13.
Zurück zum Zitat Karayan-Tapon L, Quillien V, Guilhot J et al (2010) Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97:311–322CrossRefPubMed Karayan-Tapon L, Quillien V, Guilhot J et al (2010) Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97:311–322CrossRefPubMed
14.
Zurück zum Zitat Quillien V, Lavenu A, Karayan-Tapon L et al (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 118:4201–4211CrossRefPubMed Quillien V, Lavenu A, Karayan-Tapon L et al (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 118:4201–4211CrossRefPubMed
15.
Zurück zum Zitat Ducray F, Crinière E, Idbaih A et al (2009) Alpha-internexin expression identifies 1p19q codeleted gliomas. Neurology 72:156–161CrossRefPubMed Ducray F, Crinière E, Idbaih A et al (2009) Alpha-internexin expression identifies 1p19q codeleted gliomas. Neurology 72:156–161CrossRefPubMed
16.
Zurück zum Zitat Ducray F, Mokhtari K, Crinière E et al (2011) Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 47:802–808CrossRefPubMed Ducray F, Mokhtari K, Crinière E et al (2011) Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 47:802–808CrossRefPubMed
17.
Zurück zum Zitat Yeager T, Neumann A, Englezou A et al (1999) Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59:4175–4179PubMed Yeager T, Neumann A, Englezou A et al (1999) Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59:4175–4179PubMed
18.
Zurück zum Zitat Kreth S, Heyn J, Grau S et al (2010) Identification of valid endogenous control genes for determining gene expression in human glioma. Neuro-Oncol 12:570–579CrossRefPubMedPubMedCentral Kreth S, Heyn J, Grau S et al (2010) Identification of valid endogenous control genes for determining gene expression in human glioma. Neuro-Oncol 12:570–579CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408CrossRefPubMed Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408CrossRefPubMed
20.
Zurück zum Zitat Sampl S, Pramhas S, Stern C et al (2012) Expression of telomeres in astrocytoma WHO grade 2 t0 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. Transl Oncol 5:56–65CrossRefPubMedPubMedCentral Sampl S, Pramhas S, Stern C et al (2012) Expression of telomeres in astrocytoma WHO grade 2 t0 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. Transl Oncol 5:5665CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Broccoli D, Godley LA, Donehower LA et al (1996) Telomerase activation in mouse mammary tumours: lack of telomere shortening and evidence for regulation of telomerase with RNA cell proliferation. Mol Cell Biol 16:3765–3772CrossRefPubMedPubMedCentral Broccoli D, Godley LA, Donehower LA et al (1996) Telomerase activation in mouse mammary tumours: lack of telomere shortening and evidence for regulation of telomerase with RNA cell proliferation. Mol Cell Biol 16:3765–3772CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Aubert G, Hills M, Lansdorp PM (2012) Telomere length measurement—caveats and a critical assessment of the available technologies and tools. Mut Res 730:59–67CrossRef Aubert G, Hills M, Lansdorp PM (2012) Telomere length measurement—caveats and a critical assessment of the available technologies and tools. Mut Res 730:59–67CrossRef
23.
Zurück zum Zitat Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820CrossRefPubMed Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820CrossRefPubMed
24.
Zurück zum Zitat Killela PJ, Reitman ZJ, Jiao Y et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021–6026CrossRefPubMedPubMedCentral Killela PJ, Reitman ZJ, Jiao Y et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021–6026CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Azzalin CM, Reichenbach P, Khoriauli L et al (2007) Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 318:798–801CrossRefPubMed Azzalin CM, Reichenbach P, Khoriauli L et al (2007) Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 318:798–801CrossRefPubMed
26.
Zurück zum Zitat Azzalin CM, Lingner J (2014) Telomere functions grounding on TERRA firma. Trends Cell Biol 25:29–36CrossRefPubMed Azzalin CM, Lingner J (2014) Telomere functions grounding on TERRA firma. Trends Cell Biol 25:29–36CrossRefPubMed
28.
Zurück zum Zitat Bower K, Napier CE, Cole SL et al (2012) Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of alternative lengthening of telomeres. PLoS ONE 7:e50062CrossRefPubMedPubMedCentral Bower K, Napier CE, Cole SL et al (2012) Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of alternative lengthening of telomeres. PLoS ONE 7:e50062CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Royds JA, Al Nadaf S, Wiles AK et al (2011) The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS ONE 6:e26737CrossRefPubMedPubMedCentral Royds JA, Al Nadaf S, Wiles AK et al (2011) The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS ONE 6:e26737CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722CrossRefPubMedPubMedCentral Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Heaphy CM, Subhawong AP, Hong SM et al (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:1608–1615CrossRefPubMedPubMedCentral Heaphy CM, Subhawong AP, Hong SM et al (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:1608–1615CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Yan W, Zhang W, You G et al (2012) Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS ONE 7:e30339CrossRefPubMedPubMedCentral Yan W, Zhang W, You G et al (2012) Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS ONE 7:e30339CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Leu S, von Felten S, Frank S et al (2013) IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-Oncol 15:469–479CrossRefPubMedPubMedCentral Leu S, von Felten S, Frank S et al (2013) IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-Oncol 15:469–479CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Ferrandon S, Saultier P, Carras J et al (2013) Telomere profiling: toward glioblastoma personalized medicine. Mol Neurobiol 47:64–76CrossRefPubMed Ferrandon S, Saultier P, Carras J et al (2013) Telomere profiling: toward glioblastoma personalized medicine. Mol Neurobiol 47:64–76CrossRefPubMed
35.
Zurück zum Zitat Flynn RL, Cox KE, Jeitany M et al (2015) Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347:273–277CrossRefPubMedPubMedCentral Flynn RL, Cox KE, Jeitany M et al (2015) Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347:273–277CrossRefPubMedPubMedCentral
Metadaten
Titel
Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis
verfasst von
Anne Fogli
Marie-Véronique Demattei
Laetitia Corset
Catherine Vaurs-Barrière
Emmanuel Chautard
Julian Biau
Jean-Louis Kémény
Catherine Godfraind
Bruno Pereira
Toufik Khalil
Nathalie Grandin
Philippe Arnaud
Michel Charbonneau
Pierre Verrelle
Publikationsdatum
28.07.2017
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-017-2585-7

Weitere Artikel der Ausgabe 2/2017

Journal of Neuro-Oncology 2/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.